European guidelines on the clinical management of HIV-1 tropism testing

L. P R Vandekerckhove, A. M J Wensing, R. Kaiser, F. Brun-Vézinet, B. Clotet, A. De Luca, S. Dressler, F. Garcia, A. M. Geretti, T. Klimkait, K. Korn, B. Masquelier, C. F. Perno, J. M. Schapiro, V. Soriano, A. Sönnerborg, A. M. Vandamme, C. Verhofstede, H. Walter, M. ZazziC. A B Boucher

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Viral tropism is the ability of viruses to enter and infect specific host cells and is based on the ability of viruses to bind to receptors on those cells. Testing for HIV tropism is recommended before prescribing a chemokine receptor blocker. In most European countries, HIV tropism is identified with tropism phenotype testing. New data support genotype analysis of the HIV third hypervariable loop (V3) for the identification of tropism. The European Consensus Group on clinical management of tropism testing was established to make recommendations to clinicians and clinical virologists. The panel recommends HIV-tropism testing for the following groups: drug-naive patients in whom toxic effects are anticipated or for whom few treatment options are available; patients who have poor tolerability to or toxic effects from current treatment or who have CNS pathology; and patients for whom therapy has failed and a change in treatment is considered. In general, an enhanced sensitivity Trofile assay and V3 population genotyping are the recommended methods. Genotypic methods are anticipated to be used more frequently in the clinical setting because of their greater accessibility, lower cost, and faster turnaround time than other methods. For the interpretation of V3 loop genotyping, clinically validated systems should be used when possible. Laboratories doing HIV tropism tests should have adequate quality assurance measures. Similarly, close collaboration between HIV clinicians and virologists is needed to ensure adequate diagnostic and treatment decisions.

Original languageEnglish
Pages (from-to)394-407
Number of pages14
JournalThe Lancet Infectious Diseases
Volume11
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Tropism
HIV-1
Guidelines
HIV
Poisons
Viral Tropism
Viruses
Therapeutics
Chemokine Receptors
Genotype
Pathology
Phenotype
Costs and Cost Analysis
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Vandekerckhove, L. P. R., Wensing, A. M. J., Kaiser, R., Brun-Vézinet, F., Clotet, B., De Luca, A., ... Boucher, C. A. B. (2011). European guidelines on the clinical management of HIV-1 tropism testing. The Lancet Infectious Diseases, 11(5), 394-407. https://doi.org/10.1016/S1473-3099(10)70319-4

European guidelines on the clinical management of HIV-1 tropism testing. / Vandekerckhove, L. P R; Wensing, A. M J; Kaiser, R.; Brun-Vézinet, F.; Clotet, B.; De Luca, A.; Dressler, S.; Garcia, F.; Geretti, A. M.; Klimkait, T.; Korn, K.; Masquelier, B.; Perno, C. F.; Schapiro, J. M.; Soriano, V.; Sönnerborg, A.; Vandamme, A. M.; Verhofstede, C.; Walter, H.; Zazzi, M.; Boucher, C. A B.

In: The Lancet Infectious Diseases, Vol. 11, No. 5, 05.2011, p. 394-407.

Research output: Contribution to journalArticle

Vandekerckhove, LPR, Wensing, AMJ, Kaiser, R, Brun-Vézinet, F, Clotet, B, De Luca, A, Dressler, S, Garcia, F, Geretti, AM, Klimkait, T, Korn, K, Masquelier, B, Perno, CF, Schapiro, JM, Soriano, V, Sönnerborg, A, Vandamme, AM, Verhofstede, C, Walter, H, Zazzi, M & Boucher, CAB 2011, 'European guidelines on the clinical management of HIV-1 tropism testing', The Lancet Infectious Diseases, vol. 11, no. 5, pp. 394-407. https://doi.org/10.1016/S1473-3099(10)70319-4
Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A et al. European guidelines on the clinical management of HIV-1 tropism testing. The Lancet Infectious Diseases. 2011 May;11(5):394-407. https://doi.org/10.1016/S1473-3099(10)70319-4
Vandekerckhove, L. P R ; Wensing, A. M J ; Kaiser, R. ; Brun-Vézinet, F. ; Clotet, B. ; De Luca, A. ; Dressler, S. ; Garcia, F. ; Geretti, A. M. ; Klimkait, T. ; Korn, K. ; Masquelier, B. ; Perno, C. F. ; Schapiro, J. M. ; Soriano, V. ; Sönnerborg, A. ; Vandamme, A. M. ; Verhofstede, C. ; Walter, H. ; Zazzi, M. ; Boucher, C. A B. / European guidelines on the clinical management of HIV-1 tropism testing. In: The Lancet Infectious Diseases. 2011 ; Vol. 11, No. 5. pp. 394-407.
@article{fc9f84892b0142c299e76f806bec7d0f,
title = "European guidelines on the clinical management of HIV-1 tropism testing",
abstract = "Viral tropism is the ability of viruses to enter and infect specific host cells and is based on the ability of viruses to bind to receptors on those cells. Testing for HIV tropism is recommended before prescribing a chemokine receptor blocker. In most European countries, HIV tropism is identified with tropism phenotype testing. New data support genotype analysis of the HIV third hypervariable loop (V3) for the identification of tropism. The European Consensus Group on clinical management of tropism testing was established to make recommendations to clinicians and clinical virologists. The panel recommends HIV-tropism testing for the following groups: drug-naive patients in whom toxic effects are anticipated or for whom few treatment options are available; patients who have poor tolerability to or toxic effects from current treatment or who have CNS pathology; and patients for whom therapy has failed and a change in treatment is considered. In general, an enhanced sensitivity Trofile assay and V3 population genotyping are the recommended methods. Genotypic methods are anticipated to be used more frequently in the clinical setting because of their greater accessibility, lower cost, and faster turnaround time than other methods. For the interpretation of V3 loop genotyping, clinically validated systems should be used when possible. Laboratories doing HIV tropism tests should have adequate quality assurance measures. Similarly, close collaboration between HIV clinicians and virologists is needed to ensure adequate diagnostic and treatment decisions.",
author = "Vandekerckhove, {L. P R} and Wensing, {A. M J} and R. Kaiser and F. Brun-V{\'e}zinet and B. Clotet and {De Luca}, A. and S. Dressler and F. Garcia and Geretti, {A. M.} and T. Klimkait and K. Korn and B. Masquelier and Perno, {C. F.} and Schapiro, {J. M.} and V. Soriano and A. S{\"o}nnerborg and Vandamme, {A. M.} and C. Verhofstede and H. Walter and M. Zazzi and Boucher, {C. A B}",
year = "2011",
month = "5",
doi = "10.1016/S1473-3099(10)70319-4",
language = "English",
volume = "11",
pages = "394--407",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - European guidelines on the clinical management of HIV-1 tropism testing

AU - Vandekerckhove, L. P R

AU - Wensing, A. M J

AU - Kaiser, R.

AU - Brun-Vézinet, F.

AU - Clotet, B.

AU - De Luca, A.

AU - Dressler, S.

AU - Garcia, F.

AU - Geretti, A. M.

AU - Klimkait, T.

AU - Korn, K.

AU - Masquelier, B.

AU - Perno, C. F.

AU - Schapiro, J. M.

AU - Soriano, V.

AU - Sönnerborg, A.

AU - Vandamme, A. M.

AU - Verhofstede, C.

AU - Walter, H.

AU - Zazzi, M.

AU - Boucher, C. A B

PY - 2011/5

Y1 - 2011/5

N2 - Viral tropism is the ability of viruses to enter and infect specific host cells and is based on the ability of viruses to bind to receptors on those cells. Testing for HIV tropism is recommended before prescribing a chemokine receptor blocker. In most European countries, HIV tropism is identified with tropism phenotype testing. New data support genotype analysis of the HIV third hypervariable loop (V3) for the identification of tropism. The European Consensus Group on clinical management of tropism testing was established to make recommendations to clinicians and clinical virologists. The panel recommends HIV-tropism testing for the following groups: drug-naive patients in whom toxic effects are anticipated or for whom few treatment options are available; patients who have poor tolerability to or toxic effects from current treatment or who have CNS pathology; and patients for whom therapy has failed and a change in treatment is considered. In general, an enhanced sensitivity Trofile assay and V3 population genotyping are the recommended methods. Genotypic methods are anticipated to be used more frequently in the clinical setting because of their greater accessibility, lower cost, and faster turnaround time than other methods. For the interpretation of V3 loop genotyping, clinically validated systems should be used when possible. Laboratories doing HIV tropism tests should have adequate quality assurance measures. Similarly, close collaboration between HIV clinicians and virologists is needed to ensure adequate diagnostic and treatment decisions.

AB - Viral tropism is the ability of viruses to enter and infect specific host cells and is based on the ability of viruses to bind to receptors on those cells. Testing for HIV tropism is recommended before prescribing a chemokine receptor blocker. In most European countries, HIV tropism is identified with tropism phenotype testing. New data support genotype analysis of the HIV third hypervariable loop (V3) for the identification of tropism. The European Consensus Group on clinical management of tropism testing was established to make recommendations to clinicians and clinical virologists. The panel recommends HIV-tropism testing for the following groups: drug-naive patients in whom toxic effects are anticipated or for whom few treatment options are available; patients who have poor tolerability to or toxic effects from current treatment or who have CNS pathology; and patients for whom therapy has failed and a change in treatment is considered. In general, an enhanced sensitivity Trofile assay and V3 population genotyping are the recommended methods. Genotypic methods are anticipated to be used more frequently in the clinical setting because of their greater accessibility, lower cost, and faster turnaround time than other methods. For the interpretation of V3 loop genotyping, clinically validated systems should be used when possible. Laboratories doing HIV tropism tests should have adequate quality assurance measures. Similarly, close collaboration between HIV clinicians and virologists is needed to ensure adequate diagnostic and treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=79955483926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955483926&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(10)70319-4

DO - 10.1016/S1473-3099(10)70319-4

M3 - Article

C2 - 21429803

AN - SCOPUS:79955483926

VL - 11

SP - 394

EP - 407

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 5

ER -